{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T06:33:44Z","timestamp":1768804424900,"version":"3.49.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,11,20]],"date-time":"2014-11-20T00:00:00Z","timestamp":1416441600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1007\/s11910-014-0511-3","type":"journal-article","created":{"date-parts":[[2014,11,21]],"date-time":"2014-11-21T10:57:02Z","timestamp":1416567422000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["An Update on the Use of Botulinum Toxin Therapy in Parkinson\u2019s Disease"],"prefix":"10.1007","volume":"15","author":[{"given":"Reversa","family":"Mills","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laxman","family":"Bahroo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Pagan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,11,20]]},"reference":[{"key":"511_CR1","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/mds.25292","volume":"28","author":"SL Kowal","year":"2013","unstructured":"Kowal SL, Dall TM, Chakrabarti R, Storm MV, Jain A. The current and projected economic burden of Parkinson\u2019s disease in the United States: economic burden of PD in the US. Mov Disord. 2013;28:311\u20138.","journal-title":"Mov Disord"},{"key":"511_CR2","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1002\/mds.22643","volume":"24","author":"P Barone","year":"2009","unstructured":"Barone P, Antonini A, Colosimo C, et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson\u2019s disease. Mov Disord. 2009;24:1641\u20139.","journal-title":"Mov Disord"},{"key":"511_CR3","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.parkreldis.2011.02.018","volume":"17","author":"KR Chaudhuri","year":"2011","unstructured":"Chaudhuri KR, Odin P, Antonini A, Martinez-Martin P. Parkinson\u2019s disease: the non-motor issues. Parkinsonism Relat Disord. 2011;17:717\u201323.","journal-title":"Parkinsonism Relat Disord"},{"key":"511_CR4","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1586\/14737175.6.8.1181","volume":"6","author":"A Diamond","year":"2006","unstructured":"Diamond A, Jankovic J. Treatment of advanced Parkinson\u2019s disease. Expert Rev Neurother. 2006;6:1181\u201397.","journal-title":"Expert Rev Neurother"},{"key":"511_CR5","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.toxicon.2008.11.013","volume":"54","author":"J Jankovic","year":"2009","unstructured":"Jankovic J. Disease-oriented approach to botulinum toxin use. Toxicon. 2009;54:614\u201323.","journal-title":"Toxicon"},{"key":"511_CR6","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1586\/14737175.7.6.637","volume":"7","author":"JK Sheffield","year":"2007","unstructured":"Sheffield JK, Jankovic J. Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson\u2019s disease. Expert Rev Neurother. 2007;7:637\u201347.","journal-title":"Expert Rev Neurother"},{"key":"511_CR7","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.toxicon.2012.12.004","volume":"67","author":"M Hallett","year":"2013","unstructured":"Hallett M, Albanese A, Dressler D, et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon. 2013;67:94\u2013114. This review provided recommendations for the therapeutic use of botulinum toxin based on various levels of evidence of available clinical studies supporting the efficacy and safety of each indication. Botulinum toxins were evaluated by the serotype A and B and also each formulation was studied individually. Recommendations based on the level of clinical evidence were presented for the treatment of various movement disorders including blepharospasm, hemifacial spasm, oromandibular dystonia, cervical dystonia, limb dystonia, laryngeal dystonia, tics and essential tremor.","journal-title":"Toxicon"},{"key":"511_CR8","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1212\/01.wnl.0000311389.26145.95","volume":"70","author":"DM Simpson","year":"2008","unstructured":"Simpson DM, Blitzer A, Brashear A, et al. Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70:1699\u2013706.","journal-title":"Neurology"},{"key":"511_CR9","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.toxicon.2012.10.020","volume":"67","author":"M Naumann","year":"2013","unstructured":"Naumann M, Dressler D, Hallett M, et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders. Toxicon Off J Int Soc Toxinology. 2013;67:141\u201352.","journal-title":"Toxicon Off J Int Soc Toxinology"},{"key":"511_CR10","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1212\/01.wnl.0000311390.87642.d8","volume":"70","author":"M Naumann","year":"2008","unstructured":"Naumann M, So Y, Argoff CE, et al. Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70:1707\u201314.","journal-title":"Neurology"},{"key":"511_CR11","first-page":"283","volume":"4","author":"BE Lacy","year":"2008","unstructured":"Lacy BE, Weiser K, Kennedy A. Botulinum toxin and gastrointestinal tract disorders: panacea, placebo, or pathway to the future? Gastroenterol Hepatol. 2008;4:283.","journal-title":"Gastroenterol Hepatol"},{"key":"511_CR12","first-page":"131","volume":"16","author":"D Charles","year":"2010","unstructured":"Charles D, Gill CE. Neurotoxin injection for movement disorders. Contin Minneap Minn. 2010;16:131\u201357.","journal-title":"Contin Minneap Minn"},{"key":"511_CR13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jns.2012.01.019","volume":"316","author":"D Truong","year":"2012","unstructured":"Truong D. Botulinum toxins in the treatment of primary focal dystonias. J Neurol Sci. 2012;316:9\u201314. This article reviews each formulation of Botulinum toxin type A and B for the treatment of various forms of focal dystonia. Clinical trials are presented comparing the safety, efficacy and duration of effect of the various formulations of botulinum toxin. Botulinum toxin therapy is considered to be first line therapy for the treatment of focal dystonia.","journal-title":"J Neurol Sci"},{"key":"511_CR14","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/mds.25475","volume":"28","author":"A Albanese","year":"2013","unstructured":"Albanese A et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord Off J Mov Disord Soc. 2013;28:863\u201373.","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"511_CR15","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s13311-013-0231-4","volume":"11","author":"MA Thenganatt","year":"2014","unstructured":"Thenganatt MA, Jankovic J. Treatment of dystonia. Neurotherapeutics. 2014;11:139\u201352. This review details the various treatment options for dystonia including oral medications, botulinum toxin, surgical procedures including Deep Brain stimulation, physical and other types of therapies. Clinical trials of botulinum toxin in the treatment of various forms of dystonia are presented with varying levels of supporting evidence. This article concluded that a combination of therapies is most effective in the treatment of dystonia.","journal-title":"Neurotherapeutics"},{"key":"511_CR16","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S1353-8020(01)00025-6","volume":"8","author":"J Jankovic","year":"2001","unstructured":"Jankovic J, Tintner R. Dystonia and parkinsonism. Parkinsonism Relat Disord. 2001;8:109\u201321.","journal-title":"Parkinsonism Relat Disord"},{"key":"511_CR17","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2165\/00023210-200721080-00005","volume":"21","author":"J Jankovic","year":"2007","unstructured":"Jankovic J, Stacy M. Medical management of levodopa-associated motor complications in patients with Parkinson\u2019s disease. CNS Drugs. 2007;21:677\u201392.","journal-title":"CNS Drugs"},{"key":"511_CR18","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.toxicon.2008.12.008","volume":"54","author":"M Hallett","year":"2009","unstructured":"Hallett M, Benecke R, Blitzer A, Comella CL. Treatment of focal dystonias with botulinum neurotoxin. Toxicon. 2009;54:628\u201333.","journal-title":"Toxicon"},{"key":"511_CR19","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/mds.870060206","volume":"6","author":"J Chan","year":"1991","unstructured":"Chan J, Brin MF, Fahn S. Idiopathic cervical dystonia: clinical characteristics. Mov Disord Off J Mov Disord Soc. 1991;6:119\u201326.","journal-title":"Mov Disord Off J Mov Disord Soc"},{"issue":"Suppl 7","key":"511_CR20","first-page":"VII7","volume":"253","author":"E Tolosa","year":"2006","unstructured":"Tolosa E, Compta Y. Dystonia in Parkinson\u2019s disease. J Neurol. 2006;253 Suppl 7:VII7\u201313.","journal-title":"J Neurol"},{"key":"511_CR21","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S1474-4422(05)70119-8","volume":"4","author":"R Ashour","year":"2005","unstructured":"Ashour R, Tintner R, Jankovic J. Striatal deformities of the hand and foot in Parkinson\u2019s disease. Lancet Neurol. 2005;4:423\u201331.","journal-title":"Lancet Neurol"},{"key":"511_CR22","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1136\/jnnp.2005.083170","volume":"78","author":"JJM Kruisdijk","year":"2007","unstructured":"Kruisdijk JJM, Koelman JHTM, OngerboerdeVisser BW, de Haan RJ, Speelman JD. Botulinum toxin for writer\u2019s cramp: a randomised, placebo-controlled trial and 1-year follow-up. J Neurol Neurosurg Psychiatry. 2007;78:264\u201370.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"511_CR23","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.clinph.2007.07.004","volume":"118","author":"MF Contarino","year":"2007","unstructured":"Contarino MF, Kruisdijk JJM, Koster L, et al. Sensory integration in writer\u2019s cramp: comparison with controls and evaluation of botulinum toxin effect. Clin Neurophysiol Off J Int Fed Clin Neurophysiol. 2007;118:2195\u2013206.","journal-title":"Clin Neurophysiol Off J Int Fed Clin Neurophysiol"},{"key":"511_CR24","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1212\/WNL.43.1_Part_1.183","volume":"43","author":"JK Tsui","year":"1993","unstructured":"Tsui JK, Bhatt M, Calne S, Calne DB. Botulinum toxin in the treatment of writer\u2019s cramp: a double-blind study. Neurology. 1993;43:183\u20135.","journal-title":"Neurology"},{"key":"511_CR25","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1212\/WNL.42.3.627","volume":"42","author":"DM Yoshimura","year":"1992","unstructured":"Yoshimura DM, Aminoff MJ, Olney RK. Botulinum toxin therapy for limb dystonias. Neurology. 1992;42:627\u201330.","journal-title":"Neurology"},{"issue":"Suppl 11","key":"511_CR26","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1002\/mds.20458","volume":"20","author":"J Jankovic","year":"2005","unstructured":"Jankovic J. Motor fluctuations and dyskinesias in Parkinson\u2019s disease: clinical manifestations. Mov Disord Off J Mov Disord Soc. 2005;20 Suppl 11:S11\u201316.","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"511_CR27","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/mds.870100317","volume":"10","author":"C Pacchetti","year":"1995","unstructured":"Pacchetti C, Albani G, Martignoni E, et al. \u2018Off\u2019 painful dystonia in Parkinson\u2019s disease treated with botulinum toxin. Mov Disord Off J Mov Disord Soc. 1995;10:333\u20136.","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"511_CR28","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1288\/00005537-199106000-00010","volume":"101","author":"DD Troung","year":"1991","unstructured":"Troung DD, Rontal M, Rolnick M, Aronson AE, Mistura K. Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia. Laryngoscope. 1991;101:630\u20134.","journal-title":"Laryngoscope"},{"key":"511_CR29","first-page":"345","volume":"24","author":"SG Adams","year":"1995","unstructured":"Adams SG, Hunt EJ, Irish JC, et al. Comparison of botulinum toxin injection procedures in adductor spasmodic dysphonia. J Otolaryngol. 1995;24:345\u201351.","journal-title":"J Otolaryngol"},{"key":"511_CR30","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1097\/00005537-199908000-00021","volume":"109","author":"EM Finnegan","year":"1999","unstructured":"Finnegan EM, Luschei ES, Gordon JD, Barkmeier JM, Hoffman HT. Increased stability of airflow following botulinum toxin injection. Laryngoscope. 1999;109:1300\u20136.","journal-title":"Laryngoscope"},{"key":"511_CR31","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1212\/WNL.38.8.1220","volume":"38","author":"CL Ludlow","year":"1988","unstructured":"Ludlow CL, Naunton RF, Sedory SE, Schulz GM, Hallett M. Effects of botulinum toxin injections on speech in adductor spasmodic dysphonia. Neurology. 1988;38:1220\u20135.","journal-title":"Neurology"},{"key":"511_CR32","first-page":"209","volume":"24","author":"DL Wong","year":"1995","unstructured":"Wong DL, Adams SG, Irish JC, et al. Effect of neuromuscular activity on the response to botulinum toxin injections in spasmodic dysphonia. J Otolaryngol. 1995;24:209\u201316.","journal-title":"J Otolaryngol"},{"key":"511_CR33","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/mds.20098","volume":"19","author":"CH Adler","year":"2004","unstructured":"Adler CH, Bansberg SF, Krein-Jones K, Hentz JG. Safety and efficacy of botulinum toxin type B (Myobloc) in adductor spasmodic dysphonia. Mov Disord Off J Mov Disord Soc. 2004;19:1075\u20139.","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"511_CR34","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1002\/lary.23265","volume":"123","author":"CF Sinclair","year":"2013","unstructured":"Sinclair CF, Gurey LE, Blitzer A. Oromandibular dystonia: long-term management with botulinum toxin: management of OMD with botulinum toxin. Laryngoscope. 2013;123:3078\u201383.","journal-title":"Laryngoscope"},{"key":"511_CR35","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.tripleo.2007.04.001","volume":"104","author":"KH Lee","year":"2007","unstructured":"Lee KH. Oromandibular dystonia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;104:491\u20136.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"511_CR36","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1212\/WNL.37.4.616","volume":"37","author":"J Jankovic","year":"1987","unstructured":"Jankovic J, Orman J. Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology. 1987;37:616\u201323.","journal-title":"Neurology"},{"key":"511_CR37","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/PHM.0b013e3181bc0c78","volume":"89","author":"SJ Lee","year":"2010","unstructured":"Lee SJ, McCall WD, Kim YK, Chung SC, Chung JW. Effect of botulinum toxin injection on nocturnal bruxism: a randomized controlled trial. Am J Phys Med Rehabil Assoc Acad Physiatr. 2010;89:16\u201323.","journal-title":"Am J Phys Med Rehabil Assoc Acad Physiatr"},{"key":"511_CR38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.baga.2012.01.004","volume":"2","author":"T Peeraully","year":"2012","unstructured":"Peeraully T, Tan E-K. Camptocormia in Parkinson\u2019s disease: dystonia or myopathy? Basal Ganglia. 2012;2:1\u20133.","journal-title":"Basal Ganglia"},{"key":"511_CR39","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1212\/01.wnl.0000171857.09079.9f","volume":"65","author":"SN Azher","year":"2005","unstructured":"Azher SN, Jankovic J. Camptocormia: pathogenesis, classification, and response to therapy. Neurology. 2005;65:355\u20139.","journal-title":"Neurology"},{"key":"511_CR40","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1017\/S031716710001489X","volume":"40","author":"F Rahimi","year":"2013","unstructured":"Rahimi F, Bee C, Debicki D, et al. Effectiveness of BoNT A in Parkinson\u2019s disease upper limb tremor management. Can J Neurol Sci. 2013;40:663\u20139.","journal-title":"Can J Neurol Sci"},{"key":"511_CR41","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1212\/WNL.41.8.1185","volume":"41","author":"J Jankovic","year":"1991","unstructured":"Jankovic J, Schwartz K. Botulinum toxin treatment of tremors. Neurology. 1991;41:1185\u20138.","journal-title":"Neurology"},{"key":"511_CR42","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1001\/archneur.1996.00550070055012","volume":"53","author":"SL Pullman","year":"1996","unstructured":"Pullman SL, Greene P, Fahn S, Pedersen SF. Approach to the treatment of limb disorders with botulinum toxin A. Experience with 187 patients. Arch Neurol. 1996;53:617\u201324.","journal-title":"Arch Neurol"},{"key":"511_CR43","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/mds.870090604","volume":"9","author":"RM Trosch","year":"1994","unstructured":"Trosch RM, Pullman SL. Botulinum toxin A injections for the treatment of hand tremors. Mov Disord Off J Mov Disord Soc. 1994;9:601\u20139.","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"511_CR44","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000117196","volume":"36","author":"JM Henderson","year":"1996","unstructured":"Henderson JM, Ghika JA, Van Melle G, Haller E, Einstein R. Botulinum toxin A in non-dystonic tremors. Eur Neurol. 1996;36:29\u201335.","journal-title":"Eur Neurol"},{"key":"511_CR45","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/mds.870110306","volume":"11","author":"J Jankovic","year":"1996","unstructured":"Jankovic J, Schwartz K, Clemence W, Aswad A, Mordaunt J. A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor. Mov Disord Off J Mov Disord Soc. 1996;11:250\u20136.","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"511_CR46","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1212\/WNL.56.11.1523","volume":"56","author":"MF Brin","year":"2001","unstructured":"Brin MF, Lyons KE, Doucette J, et al. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology. 2001;56:1523\u20138.","journal-title":"Neurology"},{"key":"511_CR47","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1002\/mds.21019","volume":"21","author":"SA Schneider","year":"2006","unstructured":"Schneider SA, Edwards MJ, Cordivari C, Macleod WN, Bhatia KP. Botulinum toxin A may be efficacious as treatment for jaw tremor in Parkinson\u2019s disease. Mov Disord Off J Mov Disord Soc. 2006;21:1722\u20134.","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"511_CR48","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.tripleo.2005.08.018","volume":"101","author":"J-P Meningaud","year":"2006","unstructured":"Meningaud J-P, Pitak-Arnnop P, Chikhani L, Bertrand J-C. Drooling of saliva: a review of the etiology and management options. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;101:48\u201357.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"511_CR49","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1136\/jnnp.2007.131045","volume":"79","author":"J Jankovic","year":"2008","unstructured":"Jankovic J. Parkinson\u2019s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79:368\u201376.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"511_CR50","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s004150070091","volume":"247","author":"LL Pinnington","year":"2000","unstructured":"Pinnington LL, Muhiddin KA, Ellis RE, Playford ED. Non-invasive assessment of swallowing and respiration in Parkinson\u2019s disease. J Neurol. 2000;247:773\u20137.","journal-title":"J Neurol"},{"key":"511_CR51","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00415-009-0085-1","volume":"256","author":"G Lagalla","year":"2009","unstructured":"Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo MG. Long-lasting benefits of botulinum toxin type B in Parkinson\u2019s disease-related drooling. J Neurol. 2009;256:563\u20137.","journal-title":"J Neurol"},{"key":"511_CR52","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1212\/WNL.61.9.1279","volume":"61","author":"A Lipp","year":"2003","unstructured":"Lipp A, Trottenberg T, Schink T, Kupsch A, Arnold G. A randomized trial of botulinum toxin A for treatment of drooling. Neurology. 2003;61:1279\u201381.","journal-title":"Neurology"},{"key":"511_CR53","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/mds.10420","volume":"18","author":"F Mancini","year":"2003","unstructured":"Mancini F, Zangaglia R, Cristina S, et al. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov Disord Off J Mov Disord Soc. 2003;18:685\u20138.","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"511_CR54","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/mds.20793","volume":"21","author":"G Lagalla","year":"2006","unstructured":"Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo MG. Botulinum toxin type A for drooling in Parkinson\u2019s disease: a double-blind, randomized, placebo-controlled study. Mov Disord Off J Mov Disord Soc. 2006;21:704\u20137.","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"511_CR55","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1212\/01.WNL.0000101713.81253.4C","volume":"62","author":"WG Ondo","year":"2004","unstructured":"Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson\u2019s disease. Neurology. 2004;62:37\u201340.","journal-title":"Neurology"},{"key":"511_CR56","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1212\/01.wnl.0000174433.76707.8c","volume":"65","author":"R Tintner","year":"2005","unstructured":"Tintner R, Gross R, Winzer UF, Smalky KA, Jankovic J. Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial. Neurology. 2005;65:765\u20137.","journal-title":"Neurology"},{"key":"511_CR57","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.clineuro.2003.10.012","volume":"106","author":"O Dogu","year":"2004","unstructured":"Dogu O, Apaydin D, Sevim S, Talas DU, Aral M. Ultrasound-guided versus \u2018blind\u2019 intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson\u2019s disease. Clin Neurol Neurosurg. 2004;106:93\u20136.","journal-title":"Clin Neurol Neurosurg"},{"key":"511_CR58","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1002\/mds.10586","volume":"18","author":"L Swinn","year":"2003","unstructured":"Swinn L, Schrag A, Viswanathan R, et al. Sweating dysfunction in Parkinson\u2019s disease. Mov Disord Off J Mov Disord Soc. 2003;18:1459\u201363.","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"511_CR59","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2310\/7750.2007.00012","volume":"11","author":"CA Murray","year":"2007","unstructured":"Murray CA, Cohen JL, Solish N. Treatment of focal hyperhidrosis. J Cutan Med Surg. 2007;11:67\u201377.","journal-title":"J Cutan Med Surg"},{"key":"511_CR60","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1212\/WNL.39.10.1309","volume":"39","author":"M Bushmann","year":"1989","unstructured":"Bushmann M, Dobmeyer SM, Leeker L, Perlmutter JS. Swallowing abnormalities and their response to treatment in Parkinson\u2019s disease. Neurology. 1989;39:1309\u201314.","journal-title":"Neurology"},{"key":"511_CR61","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/ageing\/23.3.251","volume":"23","author":"MR Bird","year":"1994","unstructured":"Bird MR, Woodward MC, Gibson EM, Phyland DJ, Fonda D. Asymptomatic swallowing disorders in elderly patients with Parkinson\u2019s disease: a description of findings on clinical examination and videofluoroscopy in sixteen patients. Age Ageing. 1994;23:251\u20134.","journal-title":"Age Ageing"},{"key":"511_CR62","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1136\/jnnp.63.4.456","volume":"63","author":"F Mari","year":"1997","unstructured":"Mari F, Matei M, Ceravolo MG, et al. Predictive value of clinical indices in detecting aspiration in patients with neurological disorders. J Neurol Neurosurg Psychiatry. 1997;63:456\u201360.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"511_CR63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2036.2003.01598.x","volume":"18","author":"D Gui","year":"2003","unstructured":"Gui D, Rossi S, Runfola M, Magalini SC. Botulinum toxin in the therapy of gastrointestinal motility disorders. Aliment Pharmacol Ther. 2003;18:1\u201316.","journal-title":"Aliment Pharmacol Ther"},{"key":"511_CR64","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1053\/gast.1996.v110.pm8613045","volume":"110","author":"PJ Pasricha","year":"1996","unstructured":"Pasricha PJ, Rai R, Ravich WJ, Hendrix TR, Kalloo AN. Botulinum toxin for achalasia: long-term outcome and predictors of response. Gastroenterology. 1996;110:1410\u20135.","journal-title":"Gastroenterology"},{"key":"511_CR65","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1055\/s-2002-33225","volume":"34","author":"M Neubrand","year":"2002","unstructured":"Neubrand M, Scheurlen C, Schepke M, Sauerbruch T. Long-term results and prognostic factors in the treatment of achalasia with botulinum toxin. Endoscopy. 2002;34:519\u201323.","journal-title":"Endoscopy"},{"key":"511_CR66","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1046\/j.1365-2036.2001.01065.x","volume":"15","author":"J Mikaeli","year":"2001","unstructured":"Mikaeli J, Fazel A, Montazeri G, Yaghoobi M, Malekzadeh R. Randomized controlled trial comparing botulinum toxin injection to pneumatic dilatation for the treatment of achalasia. Aliment Pharmacol Ther. 2001;15:1389\u201396.","journal-title":"Aliment Pharmacol Ther"},{"key":"511_CR67","first-page":"105","volume":"34","author":"V D\u2019Onofrio","year":"2002","unstructured":"D\u2019Onofrio V, Miletto P, Leandro G, Iaquinto G. Long-term follow-up of achalasia patients treated with botulinum toxin. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2002;34:105\u201310.","journal-title":"Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver"},{"key":"511_CR68","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1046\/j.1442-2050.2001.00189.x","volume":"14","author":"UC Ghoshal","year":"2001","unstructured":"Ghoshal UC, Chaudhuri S, Pal BB, et al. Randomized controlled trial of intrasphincteric botulinum toxin A injection versus balloon dilatation in treatment of achalasia cardia. Dis Esophagus Off J Int Soc Dis Esophagus ISDE. 2001;14:227\u201331.","journal-title":"Dis Esophagus Off J Int Soc Dis Esophagus ISDE"},{"key":"511_CR69","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1136\/gut.46.5.597","volume":"46","author":"V Annese","year":"2000","unstructured":"Annese V, Bassotti G, Coccia G, et al. A multicentre randomised study of intrasphincteric botulinum toxin in patients with oesophageal achalasia. GISMAD Achalasia Study Group. Gut. 2000;46:597\u2013600.","journal-title":"Gut"},{"key":"511_CR70","doi-asserted-by":"crossref","first-page":"S146","DOI":"10.1002\/mds.20070","volume":"19","author":"G Brisinda","year":"2004","unstructured":"Brisinda G, Bentivoglio AR, Maria G, Albanese A. Treatment with botulinum neurotoxin of gastrointestinal smooth muscles and sphincters spasms. Mov Disord. 2004;19:S146\u201356.","journal-title":"Mov Disord"},{"key":"511_CR71","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.parkreldis.2010.08.003","volume":"17","author":"RF Pfeiffer","year":"2011","unstructured":"Pfeiffer RF. Gastrointestinal dysfunction in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2011;17:10\u20135.","journal-title":"Parkinsonism Relat Disord"},{"key":"511_CR72","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1136\/jnnp.51.12.1503","volume":"51","author":"SE Mathers","year":"1988","unstructured":"Mathers SE, Kempster PA, Swash M, Lees AJ. Constipation and paradoxical puborectalis contraction in anismus and Parkinson\u2019s disease: a dystonic phenomenon? J Neurol Neurosurg Psychiatry. 1988;51:1503\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"511_CR73","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1111\/j.1572-0241.2003.07514.x","volume":"98","author":"A Albanese","year":"2003","unstructured":"Albanese A, Brisinda G, Bentivoglio AR, Maria G. Treatment of outlet obstruction constipation in Parkinson\u2019s disease with botulinum neurotoxin A. Am J Gastroenterol. 2003;98:1439\u201340.","journal-title":"Am J Gastroenterol"},{"key":"511_CR74","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1111\/j.1365-2036.2005.02669.x","volume":"22","author":"F Cadeddu","year":"2005","unstructured":"Cadeddu F, Bentivoglio AR, Brandara F, et al. Outlet type constipation in Parkinson\u2019s disease: results of botulinum toxin treatment. Aliment Pharmacol Ther. 2005;22:997\u20131003.","journal-title":"Aliment Pharmacol Ther"},{"key":"511_CR75","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/iju.12421","volume":"21","author":"R Sakakibara","year":"2014","unstructured":"Sakakibara R, Tateno F, Nagao T, et al. Bladder function of patients with Parkinson\u2019s disease: bladder function of patients with PD. Int J Urol. 2014;21:638\u201346.","journal-title":"Int J Urol"},{"key":"511_CR76","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S1566-0702(01)00295-8","volume":"92","author":"R Sakakibara","year":"2001","unstructured":"Sakakibara R, Shinotoh H, Uchiyama T, et al. Questionnaire-based assessment of pelvic organ dysfunction in Parkinson\u2019s disease. Auton Neurosci Basic Clin. 2001;92:76\u201385.","journal-title":"Auton Neurosci Basic Clin"},{"key":"511_CR77","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.juro.2009.06.023","volume":"182","author":"A Giannantoni","year":"2009","unstructured":"Giannantoni A, Rossi A, Mearini E, et al. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson\u2019s disease and multiple system atrophy. J Urol. 2009;182:1453\u20137.","journal-title":"J Urol"},{"key":"511_CR78","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.juro.2011.04.071","volume":"186","author":"A Giannantoni","year":"2011","unstructured":"Giannantoni A, Conte A, Proietti S, et al. Botulinum toxin type A in patients with Parkinson\u2019s disease and refractory overactive bladder. J Urol. 2011;186:960\u20134.","journal-title":"J Urol"},{"key":"511_CR79","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.parkreldis.2010.06.006","volume":"16","author":"H Kulaksizoglu","year":"2010","unstructured":"Kulaksizoglu H, Parman Y. Use of botulinum toxin-A for the treatment of overactive bladder symptoms in patients with Parkinsons\u2019s disease. Parkinsonism Relat Disord. 2010;16:531\u20134.","journal-title":"Parkinsonism Relat Disord"},{"key":"511_CR80","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3390\/toxins5020249","volume":"5","author":"J Ramirez-Castaneda","year":"2013","unstructured":"Ramirez-Castaneda J, Jankovic J. Long-term efficacy and safety of botulinum toxin injections in dystonia. Toxins. 2013;5:249\u201366.","journal-title":"Toxins"},{"key":"511_CR81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.toxicon.2011.04.019","volume":"58","author":"JF Baizabal-Carvallo","year":"2011","unstructured":"Baizabal-Carvallo JF, Jankovic J, Pappert E. Flu-like symptoms following botulinum toxin therapy. Toxicon Off J Int Soc Toxinology. 2011;58:1\u20137.","journal-title":"Toxicon Off J Int Soc Toxinology"},{"key":"511_CR82","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s12640-013-9400-9","volume":"24","author":"JF Baizabal-Carvallo","year":"2013","unstructured":"Baizabal-Carvallo JF, Jankovic J, Feld J. Flu-like symptoms and associated immunological response following therapy with botulinum toxins. Neurotox Res. 2013;24:298\u2013306.","journal-title":"Neurotox Res"},{"key":"511_CR83","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1136\/jnnp.2003.034702","volume":"75","author":"J Jankovic","year":"2004","unstructured":"Jankovic J. Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry. 2004;75:951\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-014-0511-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11910-014-0511-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-014-0511-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T06:34:03Z","timestamp":1717569243000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11910-014-0511-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,20]]},"references-count":83,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["511"],"URL":"https:\/\/doi.org\/10.1007\/s11910-014-0511-3","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,20]]},"article-number":"511"}}